2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Rafael Fonseca, MD, discusses the shift toward frontline quadruplet regimens in multiple myeloma.
Rafael Fonseca, MD, interim director of Mayo Clinic Cancer Center and director, Innovation and Transformational Relationships at Mayo Clinic, discusses the shift toward frontline quadruplet regimens in multiple myeloma.
Treatment in multiple myeloma is beginning to shift away from doublet or triplet therapies in favor of quadruplet regimens in the frontline setting, says Fonseca. Although questions regarding insurance coverage, reimbursement, and toxicity remain unanswered, quadruplet regimens can offer effective and intensive options to patients with multiple myeloma, Fonseca explains.
Data have demonstrated that patients who receive the most effective therapies up front derive the best survival outcomes, says Fonseca. Moreover, high levels of attrition have been observed in multiple myeloma. As such, some patients who experience progression may not be fit enough to receive the therapies that were reserved for later-line settings, concludes Fonseca.